伐昔洛韦用于中重度慢阻肺EBV抑制的随机双盲安慰剂对照试验
EViSCO试验为随机双盲安慰剂对照研究,纳入84例稳定期中重度COPD且痰EBV阳性的患者,随机分配至伐昔洛韦1g每日三次或安慰剂治疗8周。结果显示伐昔洛韦组EBV抑制率显著高于安慰剂组(87.8% vs 42.5%,P<.001),且痰EBV滴度显著下降(P=.002),FEV1无显著差异,但痰白细胞计数降低(P=.003)。结论认为伐昔洛韦安全有效抑制EBV并可能减轻气道炎症。
要点
- 伐昔洛韦8周治疗可显著抑制中重度COPD患者痰EBV(87.8% vs 42.5%)。
- 伐昔洛韦组痰EBV滴度降幅显著大于安慰剂组(P=.002)。
- FEV1无显著改善,但痰白细胞计数显著降低(P=.003)。
核心结论
- 伐昔洛韦对COPD患者痰EBV抑制安全有效,并可能减轻痰炎症细胞浸润。
研究设计与样本
- 随机双盲安慰剂对照试验,在英国贝尔法斯特Mater医院进行,84例稳定期中重度COPD且痰EBV阳性患者按1:1随机分配至伐昔洛韦1g每日三次或安慰剂治疗8周。
主要发现
- 伐昔洛韦组EBV抑制(痰病毒载量下降≥90%)比例显著高于安慰剂组(36例[87.8%] vs 17例[42.5%],P<.001)。
- 伐昔洛韦组痰EBV滴度降幅显著大于安慰剂组(-90,404 copies/mL vs -3,940 copies/mL,P=.002)。
- FEV1组间差异无统计学意义(差异-44 mL,95%CI -150至62 mL,P=.41)。
- 伐昔洛韦组痰白细胞计数较安慰剂组显著降低(差异2.89,95%CI 1.5×10^6-7.4×10^6,P=.003)。
关键数值与推荐
- 主要疗效结局为第8周痰EBV抑制,定义为痰病毒载量下降≥90%。
- 主要安全性结局为严重不良反应发生率。
临床怎么用
- 对于稳定期中重度COPD且痰EBV阳性的患者,可考虑伐昔洛韦8周疗程以抑制EBV并可能减轻气道炎症。
- 伐昔洛韦对FEV1无显著改善,不应以改善肺功能为主要目的使用。
局限性
- 样本量较小(84例随机),随访仅8周,缺乏长期临床结局数据。
- 研究仅在单中心进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epstein-Barr virus (EBV) frequently is measured at high levels in COPD using sputum quantitative polymerase chain reaction, whereas airway immunohistochemistry analysis has shown EBV detection to be common in severe disease. RESEARCH QUESTION: Is valaciclovir safe and effective for EBV suppression in COPD? STUDY DESIGN AND METHODS: The Epstein-Barr Virus Suppression in COPD (EViSCO) trial was a randomized double-blind placebo-controlled trial conducted at the Mater Hospital Belfast, Northern Ireland. Eligible patients had stable moderate-to-severe COPD and sputum EBV (measured using quantitative polymerase chain reaction) and were assigned randomly (1:1) to valaciclovir (1 g tid) or matching placebo for 8 weeks. The primary efficacy outcome was sputum EBV suppression (defined as ≥ 90% sputum viral load reduction) at week 8. The primary safety outcome was the incidence of serious adverse reactions. Secondary outcome measures were FEV1 and drug tolerability. Exploratory outcomes included changes in quality of life, sputum cell counts, and cytokines. RESULTS: From November 2, 2018, through March 12, 2020, 84 patients were assigned randomly (n = 43 to valaciclovir). Eighty-one patients completed trial follow-up and were included in the intention-to-treat analysis of the primary outcome. A greater number of participants in the valaciclovir group achieved EBV suppression (n = 36 [87.8%] vs n = 17 [42.5%]; P < .001). Valaciclovir was associated with a significant reduction in sputum EBV titer compared with placebo (-90,404 copies/mL [interquartile range, -298,000 to -15,200 copies/mL] vs -3,940 copies/mL [interquartile range, -114,400 to 50,150 copies/mL]; P = .002). A statistically nonsignificant 24-mL numerical FEV1 increase was shown in the valaciclovir group (difference, -44 mL [95% CI, -150 to 62 mL]; P = .41). However, a reduction in sputum white cell count was noted in the valaciclovir group compared with the placebo group (difference, 2.89 [95% CI, 1.5 × 106-7.4 × 106]; P = .003). INTERPRETATION: Valaciclovir is safe and effective for EBV suppression in COPD and may attenuate the sputum inflammatory cell infiltrate. The findings from the current study provide support for a larger trial to evaluate long-term clinical outcomes. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03699904; URL: www. CLINICALTRIALS: gov.
引用
- Linden DA, Guo-Parke H, McKelvey MC, et al. Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD: A Randomized Double-Blind Placebo-Controlled Trial. Chest. 2023. PMID: 37011709. doi:10.1016/j.chest.2023.03.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。